Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles